

ACETO CORP  
Form 8-K  
September 11, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): September 5, 2014

Aceto Corporation

(Exact Name of Registrant as Specified in its Charter)

New York

000-04217

11-1720520

(State or Other Jurisdiction of Incorporation) (Commission File Number)

(IRS Employer

Identification No.)

4 Tri Harbor Court, Port Washington, NY 11050

Edgar Filing: ACETO CORP - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (516) 627-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

Aceto Corporation announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, has completed the purchase of three Abbreviated New Drug Applications (ANDAs) from Par Pharmaceutical, Inc., acquiring Doxercalciferol, Paricalcitol and Dutasteride Capsules. All of the products utilize soft gel capsule technology. The purchase price included \$750,000 paid at closing plus up to \$5.5 million based upon FDA approval of Doxercalciferol and Dutasteride and launch milestones for all three products. It is anticipated that an additional approximately \$1.9 million in development, inventory and other deal costs will be expended in connection with the transaction.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No. Description

99.1 Press Release, dated September 8, 2014

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACETO CORPORATION

Dated: September 11, 2014 By: /s/ Salvatore Guccione  
Salvatore Guccione  
President and CEO